LENZ Therapeutics Inc
(NAS:LENZ)
$
5.51
-0.070 (-1.25%)
Market Cap: 172.76 Mil
Enterprise Value: -84.95 Mil
PE Ratio: 0
PB Ratio: 0.70
GF Score: 12/100 LENZ Therapeutics Inc at Citi Global Healthcare Conference Transcript
Dec 04, 2025 / 03:30PM GMT
Release Date Price:
$27.9
(-0.36%)
Yigal Nochomovitz;Douala Branch;Analyst
Citibank Cameroon SA
()-
Welcome, everyone, to the 3rd day of City's Global Healthcare conference. I'm Yigal Nacheovitz, Biotech analyst, here at CI. So we have a really super interesting company, next, it's Lenss Therapeutics. I have with me the CEO Ai Shimmel Pennik.
Thank you, Ai, so much for joining.
Questions & Answers
Yigal Nochomovitz;Douala Branch;Analyst
Citibank Cameroon SA
()-
Obviously, a tremendous amount of progress, since you, did the reverse merge, did the phase 3 data, successfully, built the commercial infrastructure, got the approval, and now, Of course have launched the product. So tell us where you are. Tell us a little bit about the early launch, how it's going, what you're preparing for one que, just, set the stage.
Evert Schimmelpennink
LENZ Therapeutics Inc - President, Chief Executive Officer, Director
Absolutely, thanks, Miguel. Obviously, thanks for the invite.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot